Abstract
Introduction
The selective estrogen receptor modulator, Tamoxifen (TAM), is one of the most frequently prescribed drugs for the treatment of breast cancer; however, its effects on the cognition of users have not been adequately studied. Although TAM is an effective anti-estrogen that blocks tumour growth in the breast, it could also influence the activity of other target estrogen sites, including the brain. The exact nature of this interaction is unknown.
Methods
A cross-sectional design was used to compare cognitive task performance of two treatment groups: 1) women using TAM for the treatment of early breast cancer (n = 23); and 2) age-matched, healthy women not using TAM (n = 23). All participants were pre-menopausal, and recipients of chemotherapy were excluded from the study.
Results
It was found that TAM users scored significantly worse than controls on tasks of immediate and delayed visual memory, verbal fluency, immediate verbal memory, visuo-spatial ability, and processing speed.
Discussions/Conclusions
Although limited by the lack of baseline data and pre-morbid intelligence measures, the results of this exploratory study suggest that at least in pre-menopausal women, TAM may exert a widespread negative influence on cognitive abilities.
Implications for Cancer Survivors
Larger, randomized, prospective trials are required to confirm these results; however, TAM use in pre-menopausal breast cancer may be associated with cognitive difficulties. Knowledge and understanding of these complications will be important for professionals in communicating both the benefits and risks of TAM use in breast cancer survivors.
Similar content being viewed by others
References
Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of Tamoxifen for breast cancer: Twenty-eight years later. J Clin Oncol 1995;13:513–29.
Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609–18. doi:10.1056/NEJM199811263392207.
Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002;20:485–93. doi:10.1200/JCO.20.2.485.
Castellon SA, Ganz PA, Bower JE, Peterson L, Abraham L, Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 2004;26:955–69. doi:10.1080/13803390490510905.
Bender CM, Sereika SM, Berga SL, Vogel VG, Brufsky AM, Paraska KK, et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncol 2006;15:422–30. doi:10.1002/pon.964.
van Dam FSAM, Schagen SB, Muller MJ, Boogerd W, van der Wall E, Droogleever Fortuyn ME, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high dose versus standard dose chemotherapy. J Natl Cancer Inst 1998;90:210–8. doi:10.1093/jnci/90.3.210.
McEwen B, Alves SE. Estrogen action in the CNS. Endocr Rev 1999;20:279–307. doi:10.1210/er.20.3.279.
Woolley C. Effects of estrogen in the CNS. Curr Opin Neurobiol 1999;9:349–54. doi:10.1016/S0959-4388(99)80051-8.
Wooley C, McEwen B. Estradiol mediates fluctuation in hippocampal synapse density during the estrous cycle in the adult rat. J Neurosci 1992;12:2549–54.
Berman KF, Schmidt PJ, Rubinow DR, Danaceau MA, VanHorn JD, Esposito G, et al. Modulation of cognition-specific cortical activity by gonadal steroids: a positron-emission tomography study in women. Proc Natl Acad Sci USA 1997;94:8836–41. doi:10.1073/pnas.94.16.8836.
Birge SJ, McEwen BS, Wise PM. Effects of estrogen deficiency on brain function. Postgrad Med. 2001, S11–S15, (March).
Eberling JL, Wu C, Tong-Turnbeaugh R, Jagust WJ. Estrogen- and tamoxifen-associated effects on brain structure and function. Neuroimage 2004;21:364–71. doi:10.1016/j.neuroimage.2003.08.037.
Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, Nilsson S. Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists. Mol Pharmacol 1998;54:105–12.
Hampson E. Variations in sex-related cognitive abilities across the menstrual cycle. Brain Cogn 1990;14:26–43. doi:10.1016/0278-2626(90)90058-V.
Kimura D. Estrogen replacement therapy may protect against intellectual decline in post-menopausal women. Horm Behav 1995;29:312–21. doi:10.1006/hbeh.1995.1022.
Phillips SM, Sherwin B. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 1992;17:497–506. doi:10.1016/0306-4530(92)90008-U.
Sherwin B, Tulandi T. “Add-back” estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with Leiomyomata Uteri. J Clin Endocrin Metab 1996;81:2545–49. doi:10.1210/jc.81.7.2545.
Duff SJ, Hampson E. A beneficial effect of estrogen on working memory in post-menopausal women taking hormone replacement therapy. Horm Behav 2000;38:262–76. doi:10.1006/hbeh.2000.1625.
Keenan PA, Ezzat WH, Ginsburg K, Moore GJ. Prefrontal cortex as the site of estrogen’s effect on cognition. Psychoneuroendocrinology 2001;26:577–90. doi:10.1016/S0306-4530(01)00013-0.
Grigorova M, Sherwin BB, Tulandi T. Effects of treatment with leuprolide acetate depot on working memory and executive functions in young premenopausal women. Psychoneuroendocrinology 2006;31:935–47. doi:10.1016/j.psyneuen.2006.05.004.
Silverman I, Phillips K. Effects of estrogen changes during the menstrual cycle on spatial performance. Ethol Sociobiol 1993;14:257–70. doi:10.1016/0162-3095(93)90021-9.
Brezden CB, Phillips K, Abdolell M, Bunston T, Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000;18:2695–701.
Paraska KK, Bender CM. Cognitive dysfunction following adjuvant chemotherapy for breast cancer: two case studies. Oncol Nurs Forum 2003;30:473–78. doi:10.1188/03.ONF.473-478.
Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with, breast carcinoma. Cancer 2004;100:2292–9. doi:10.1002/cncr.20272.
Paganini-Hill A, Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 2000;64:165–76. doi:10.1023/A:1006426132338.
Shilling V, Jenkins V, Fallowfield L, Howell T. The effects of hormone therapy on cognition in breast cancer. J Steroid Biochem 2003;86:405–12. doi:10.1016/j.jsbmb.2003.07.001.
McNair DM, Lorr M, Droppleman LF. Profile of mood states. San Diego, California: EdITS/Educational and Industrial Testing Service; 1992.
Meyers J, Meyers K. The Meyers scoring system for the Rey complex figure and recognition trial: professional manual. Odessa, FA: Psychological Assessment Resources; 1995.
Wechsler D. Wechsler memory scale. 3rd ed. San Antonio, TX: The Psychological Corporation; 1997.
Vandenberg SG, Kuse AR. Mental rotations: a group test of three-dimensional spatial visualization. Percept Mot Skills 1978;47:599–604.
Wechsler D. Wechsler adult intelligence scale-III. New York, NY: The Psychological Corporation; 1991.
Spreen O, Strauss E. A compendium of neuropsychological tests. 2nd ed. New York, NY: Oxford University; 1998. p. 263–7. 447–464.
Kimura D. Sex and cognition. Cambridge, MA: MIT; 1999.
Cimprich B, Ronis DL. Attention and symptom distress in women with and without breast cancer. Nurs Res 2001;50:86–94. doi:10.1097/00006199-200103000-00004.
Hurria A, Rosen C, Hudis C, Zuckerman E, Panageas KS, Lachs MS. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: A pilot prospective longitudinal study. J Am Geriatr Soc 2006;54:925–31. doi:10.1111/j.1532-5415.2006.00732.x.
Wefel JS, Lenzi R, Theriault R, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast cancer. Cancer 2004;100:2292-9. doi:10.1002/cncr.20272.
Yeudall LT, Fromm D, Reddon JR, Stefanyk WO. Normative data stratified by age and sex for 12 neuropsychological tests. J Clin Psychol 1986;42:918–46. doi:10.1002/1097-4679(198611)42:6<918::AID-JCLP2270420617>3.0.CO;2-Y.
Lafayette Instrument Company. Instructions and normative data for model 32020 Purdue Pegboard. Lafayette, IN: Lafayette Instrument Company; 1985.
Eals M, Silverman I. The hunter-gatherer theory of spatial sex differences: proximate factors mediating the female advantage in recall of object arrays. Ethol Sociobiol 1994;15:95–105. doi:10.1016/0162-3095(94)90020-5.
Silverman I, Eals M. Sex differences in spatial abilities: evolutionary theory and data. In: Barkow J, Cosmides L, Tooby J, editors. The adapted mind: evolutionary psychology and the generation of culture. New York, NY: Oxford University Press; 1992. p. 487–503.
Kaplan EF, Goodglass H, Weintraub S. The Boston naming test. 2nd ed. Austin, TX: Pro-Ed; 2001.
Acknowledgements
This research was funded by a grant from the Alberta Cancer Board through the Tom Baker Cancer Centre Clinical Research Unit. Dr. Carlson holds the Enbridge Endowed Research Chair in Psychosocial Oncology and an Alberta Heritage Foundation for Medical Research Health Scholar Award.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Palmer, J.L., Trotter, T., Joy, A.A. et al. Cognitive effects of Tamoxifen in pre-menopausal women with breast cancer compared to healthy controls. J Cancer Surviv 2, 275–282 (2008). https://doi.org/10.1007/s11764-008-0070-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11764-008-0070-1